New staph vaccine shows promise in early human trial

NCT ID NCT06719219

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new vaccine called LTB-SA7 designed to protect against infections caused by Staphylococcus aureus bacteria. 129 healthy adults received either the vaccine or a placebo to check for safety and to see if the vaccine triggers an immune response. The study is complete, and researchers are analyzing how well the vaccine is tolerated and whether it produces antibodies against seven key toxins.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAPHYLOCOCCUS (S.) AUREUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

staphylococcus aureus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Naval Medical Research Command Clinical Trial Center

    Bethesda, Maryland, 20889, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.